ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » North Carolina » Cardiovascular Disease

Top Cardiovascular Disease Prescribers in North Carolina

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
ERIC JANIS M.D.

Cardiovascular Disease

17,961

$885K

1275
983 are 65+

1%
patients receiving schedule two controlled substances

Avg: 1%

4%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 25%

$49
Average prescription price

Avg: $57

FRANKLIN WEFALD M.D.

Cardiovascular Disease

17,726

$1.5M

951
672 are 65+

17%
patients receiving schedule two controlled substances

Avg: 1%

8%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

34%
prescriptions for brand name drugs

Avg: 25%

$85
Average prescription price

Avg: $57

LINDSEY WHITE MD

Cardiovascular Disease

15,286

$926K

1203
1013 are 65+

2%
patients receiving schedule two controlled substances

Avg: 1%

5%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 25%

$61
Average prescription price

Avg: $57

MATTHEW BLOCK MD

Cardiovascular Disease

13,637

$433K

1002
671 are 65+

4%
patients receiving schedule two controlled substances

Avg: 1%

13%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

18%
prescriptions for brand name drugs

Avg: 25%

$32
Average prescription price

Avg: $57

CHI LAI MD

Cardiovascular Disease

12,726

$711K

516
415 are 65+

6%
patients receiving schedule two controlled substances

Avg: 1%

15%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

36%
prescriptions for brand name drugs

Avg: 25%

$56
Average prescription price

Avg: $57

THOMAS BRACKBILL M.D.

Cardiovascular Disease

11,453

$574K

626
587 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

3%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 25%

$50
Average prescription price

Avg: $57

MAHMOUD ATIEH MD

Cardiovascular Disease

10,966

$561K

783
637 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 25%

$51
Average prescription price

Avg: $57

RICHARD WEINTRAUB MD FACC

Cardiovascular Disease

10,292

$482K

594
506 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 25%

$47
Average prescription price

Avg: $57

WILLIE SESSIONS M.D.

Cardiovascular Disease

10,150

$437K

733
541 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 25%

$43
Average prescription price

Avg: $57

ROGER SEAGLE M.D.

Cardiovascular Disease

10,144

$619K

452
370 are 65+

6%
patients receiving schedule two controlled substances

Avg: 1%

10%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 25%

$61
Average prescription price

Avg: $57

BRIAN MUNLEY M.D.

Cardiovascular Disease

9,971

$477K

810
706 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 25%

$48
Average prescription price

Avg: $57

MOHAN HARWANI M.D.

Cardiovascular Disease

9,925

$492K

489
363 are 65+

3%
patients receiving schedule two controlled substances

Avg: 1%

2%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 25%

$50
Average prescription price

Avg: $57

THOMAS KELLY M.D. FACC

Cardiovascular Disease

9,379

$561K

515
450 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

33%
prescriptions for brand name drugs

Avg: 25%

$60
Average prescription price

Avg: $57

LINDA CALHOUN MD

Cardiovascular Disease

9,336

$671K

552
471 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

34%
prescriptions for brand name drugs

Avg: 25%

$72
Average prescription price

Avg: $57

JAMES BRADFORD M.D.

Cardiovascular Disease

9,115

$384K

657
586 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

2%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 25%

$42
Average prescription price

Avg: $57

OMATTA SIRISENA M.D.

Cardiovascular Disease

8,812

$406K

235
163 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

18%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 25%

$46
Average prescription price

Avg: $57

JONATHAN BERRY MD FACC

Cardiovascular Disease

8,787

$492K

677
574 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 25%

$56
Average prescription price

Avg: $57

DANIEL ANDREWS MD

Cardiovascular Disease

8,700

$458K

615
538 are 65+

3%
patients receiving schedule two controlled substances

Avg: 1%

12%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 25%

$53
Average prescription price

Avg: $57

BENJAMIN ATKESON M.D.

Cardiovascular Disease

8,663

$454K

802
601 are 65+

2%
patients receiving schedule two controlled substances

Avg: 1%

3%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 25%

$52
Average prescription price

Avg: $57

JAVED MASOUD MD

Cardiovascular Disease

8,628

$458K

378
288 are 65+

5%
patients receiving schedule two controlled substances

Avg: 1%

8%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 25%

$53
Average prescription price

Avg: $57

LINDA SHUCK DO

Cardiovascular Disease

8,417

$662K

562
253 are 65+

53%
patients receiving schedule two controlled substances

Avg: 1%

14%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 25%

$79
Average prescription price

Avg: $57

GEORGE BECKWITH MD

Cardiovascular Disease

8,272

$589K

345
305 are 65+

3%
patients receiving schedule two controlled substances

Avg: 1%

9%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

36%
prescriptions for brand name drugs

Avg: 25%

$71
Average prescription price

Avg: $57

ARCHIE TYSON M.D.

Cardiovascular Disease

8,252

$354K

660
574 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 25%

$43
Average prescription price

Avg: $57

GUY DE GENT M.D.

Cardiovascular Disease

8,139

$254K

604
475 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

16%
prescriptions for brand name drugs

Avg: 25%

$31
Average prescription price

Avg: $57

NAIM BOUHUSSEIN M.D.

Cardiovascular Disease

7,935

$328K

695
612 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 25%

$41
Average prescription price

Avg: $57

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank